malaria infection. 7, 8 In Kudat District of the Sarawak neighbourstate Sabah, some 78% of 220 malaria-positive patients were considered to be afflicted with P. knowlesi mono-infections and 9% with mixed infections, 8 while in Sandakan Division, 23.6% were reported to be positive for this Plasmodium species. 10 Another study in which nested PCR was used in Sabah, showed 63 P. knowlesi single infections and two mixed infections out of 107 Plasmodium spppositive samples. 9 The analysis of archival blood films suggests that, already in 1996, P. knowlesi accounted for a large part of microscopically diagnosed Plasmodium malariae infections in Sarawak, 11 and according to the more recent investigations, it appears to have increased in recent decades. 12 Also, this Plasmodium species has been detected in different states of Peninsular Malaysia. 13, 14 However the fifth malaria parasite is not geographically limited to Malaysian Borneo and the Malaysian mainland. In Thailand, the existence of P. knowlesi has been reported at different locations throughout the country. [15] [16] [17] In Vietnam, three cases have been reported from Ninth Thuan Province 18 and 32 PCR-positive blood samples from Nga Hai and Da Tai (Khanh Hoa Province). 19 Six more cases have been reported in the forested part of Singapore, 20,21 32 from southern Myanmar, 22 six from the Philippine island of Palawan, 23 and two cases have been described in Cambodia near the border with Thailand. 24 P. knowlesi is transmitted by mosquitoes of the Anopheles leucosphyrus group. 13, 25, 26 The natural hosts include long-tailed macaques (M. fascicularis), pig-tailed macaques (Macaca nemestrina), and banded leaf monkeys (Presbytis melalophos). 27 The prevalence of infection in long-and pig-tailed macaques in Kapit Division (Sarawak, Malaysia) is up to 78%. 28 For intercontinental travellers, the significance of P. knowlesi infections became clear when, in 2006, a Swedish traveller presented to a Stockholm hospital with a P. knowlesi-positive blood picture after a 2-week holiday in Sarawak, Malaysian Borneo. 29 Since then, there have been several reports of imported P. knowlesi cases all over the world. [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] This review presents an overview of available knowledge on Plasmodium knowlesi with a focus on the risk of travel-associated acquisition of this malaria species. (Figs. 1 and 2) 
Methods
The data were compiled from searches of PubMed using the following search terms, alone or in combination: ''Plasmodium knowlesi'', ''Plasmodium knowlesi infections'', ''Plasmodium knowlesi travellers'', ''Plasmodium knowlesi prevalence'', ''Plasmodium knowlesi host'', ''Plasmodium knowlesi vector'', ''Plasmodium knowlesi RDT'', and ''Plasmodium knowlesi Malaysia''. References of the selected articles were also searched to complete the documentation. Traveller numbers to Malaysia were sourced from the website of Tourism Malaysia. The cut-off date for the collation of information was December 1, 2013.
Results and discussion
We used a selection of the 103 papers resulting from our PubMed screening, with the addition of further papers identified from the references lists. Furthermore we used statistics on tourism in Malaysia obtained from the official website of Tourism Malaysia. (Table 1) The first reported case of a naturally transmitted P. knowlesi infection concerned a surveyor from the US Army in 1965. 4 This early report suggested that the parasite could also be a threat to international occupational and holiday travellers. Since then, further cases of P. knowlesi infection probably acquired during a holiday or work-related trip have been reported from non-endemic countries in Asia (n = 2), 40, 41 as well as from other continents (n = 11). [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] In Europe, the two first confirmed imported P. reported cases in intercontinental travellers, only three cases involved female patients. 31, 37, 39 The period of travel in the risk area varied from 1 week to several months. 4, [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] In nearly all cases, a history of travel to a forested area with overnight stays was included. 4, 29, 30, [32] [33] [34] [35] 37, 38 No stay in a forest was reported for only two cases, a female patient visiting relatives on Palawan Island in the Philippines 31 and a French tourist spending his holidays on a tourist beach on the Island of Ko Pyang in Thailand 36 . In both cases, however, the travellers were on the edge of a forested area, but never entered it.
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Clinical and laboratory parameters
In a clinical study, Daneshvar et al. reported fever and chills to be the common symptoms, identified in 100% of the investigated cases. 6 Furthermore headache, rigors, malaise, anorexia, myalgia, arthralgia, cough, and abdominal pain were frequently observed. Tachycardia and tachypnea were noted as common clinical signs. 6, 42 In the 12 intercontinental traveller cases, the first common symptom was fever. Other symptoms were headache (n = 6), chills (n = 6), nausea (n = 4), myalgia (n = 3), back pain (n = 3), abdominal problems (n = 1), anorexia (n = 2), fatigue (n = 2), malaise (n = 1), arthralgia (n = 1), sore throat (n = 2) vomiting (n = 1), and jaundice (n = 1). 4, [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] In one case, symptoms of hypoglycaemia with slight hearing and visual loss were reported during treatment with quinine and doxycycline. 30 In most cases, the first clinical symptoms were present 2-13 days after leaving the country of probable acquisition. Only in the case of a 32-year-old Dutch woman were the symptoms already present in the country travelled to. 37 Clinical examination showed an increased temperature (range 38.8-40.2 8C) in all 12 traveller patients. 4, [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] In only three of 10 cases in whom it was measured, was anaemia found to be present. 29, 33, 38 Leukocyte counts were lowered in five cases. 29, 30, 32, 34, 37 Thrombocytopenia was present in all patients in whom platelet levels were determined. [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] Six publications reported an increase in the liver enzyme alanine aminotransferase and five an increased aspartate aminotransferase. 29, 32, 33, 36, 37 Renal failure was diagnosed with an increase in creatinine up to 3.45 mg/ dl in a German woman. 39 According to the adapted World Health Organization (WHO) criteria for severe malaria infection by Barber et al., two of the traveller cases could be considered to have had severe infections. In one case this was due to high parasite and bilirubin levels, 33 and in another to rising creatinine levels during hospitalization. 39, 42 Concerning the prognosis, Willmann et al. postulated that patients with P. knowlesi infections and a parasite count !35 000/ml or !1%, or a platelet count 45 Â 10 9 /l, should be considered as at risk of further complications. 43 On the other hand Barber et al. reported a correlation only with parasitemia (!20 000/ml) as a significant marker of severity. 42 Therefore, according to Willmann et al., two more patients could be considered to have been at potential risk of further complications because of their low platelet levels or high parasitemia, 29, 31, 33, 43 and a further case also by the criteria of Barber et al. 4, 42 (Table 1 and Table 2) 3.3. Diagnosis of P. knowlesi malaria
The 'gold standard' for the diagnosis of most Plasmodium species is microscopic examination because it is rapid and inexpensive and accurate in expert hands. The disadvantage in its application for the diagnosis of P. knowlesi is the large number of false-negatives or misdiagnosed cases due to the morphological similarity with P. falciparum in the early trophozoite stage and with P. malariae in the late and mature trophozoites, gametocytes, and schizonts. 5, 44 The first nested PCR applied to P. knowlesi diagnosis was described by Singh et al. 5 However, in its application, the primer pair resulted in a small number of false-positive results due to cross-reactivity with Plasmodium vivax. 45 Since then, additional nested PCR primers and real-time PCR procedures with a higher sensitivity have been developed. [45] [46] [47] [48] Although PCR is one of the most sensitive and specific known diagnostic methods, it requires time, money, and well-trained personnel, and for these reasons it is not ideal in most settings. 49 Currently available rapid diagnostic tests (RDTs) based on monoclonal antibodies (MAbs) capturing pan-Plasmodium lactate dehydrogenase (pan-pLDH) and genus-specific aldolase (panaldolase), only have a sensitivity of 74% and 23%, respectively, and do not distinguish between the non-falciparum species. 50 In 53 The exact niche for this diagnostic approach has yet to be established.
Treatment and chemoprophylaxis
The most frequently reported drug treatment for P. knowlesi infections in the papers reviewed was a combination of chloroquine and primaquine. [4] [5] [6] 8, 23, 54 Due to the fact that no hypnozoites have ever been described in P. knowlesi infections, primaquine is probably not required as a treatment, except in cases of mixed infection with P. vivax. In one study, the time to clear 90% of the parasitemia present at admission was defined as 10.3 h with a fever remission time of 26.5 h in adults. The dosage used was 25 mg/kg chloroquine over 2 days and additionally 15 mg primaquine. 54 Children with the same drug combination showed a much slower mean parasite clearance of 2 days. A significant correlation has been shown between the parasite concentration in the blood and the time to parasite clearance. 8 A recent study revealed the efficiency of artemisinin-based combination therapy (ACT) with artemether-lumefantrine and artesunate-mefloquine for non-severe P. knowlesi infections, or intravenous artesunate for severe infections. 42 A faster parasite clearance was reported with artemether-lumefantrine and artesunate compared to chloroquine and quinine. 42 Even if at the present time, large studies on the other established malaria treatments are missing, several single reports have underlined the efficiency of the different currently available drugs. The documented successful treatment with different combinations of chloroquine, primaquine, artemisinin combinations, sulfadoxine, pyrimethamine, and quinine are shown in Table 5 . Mefloquine was described three times as an effective therapy. 24, 29, 40 In another case report involving a re-infected Malaysian businessman during an expedition in Tanjung Malim, Perak, Malaysia, the parasitemia continued to increase despite a total administration of 1.5 g of mefloquine.
The man, who presented symptoms of chills, rigors, epigastric pain, nausea, and vomiting after an expedition with overnight camping, was started on initial therapy of 750 mg mefloquine with two successive doses of 500 mg after 6 h and 250 mg after 12 h. Despite treatment, the parasitemia increased from 1.0% to 2.5%. Medication was changed to quinine, doxycycline, and the combination artemether and lumefantrine. Parasitemia eventually cleared on day 5 of admission to the hospital. 55 There may be potential resistance of some P. knowlesi strains against mefloquine. Experiments with infected rhesus monkeys showed a suppressive activity of mefloquine but without complete cure against P. knowlesi infections. 56, 57 Recent studies have indicated an innate immunity to mefloquine in vitro, as well in ex vivo experiments.
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Data regarding chemoprophylaxis for prevention are missing, but the fact that none of the infected cases reported so far had received adequate prophylaxis could indicate an effect of known preventive anti-malaria drugs against P. knowlesi as well. Only one case, a Spanish traveller, had used mefloquine and later atovaquone/proguanil chemoprophylaxis; this case developed a mild P. knowlesi infection but later recovered without further treatment. 32 (Table 3, Table 4 and Table 5 ).
Risk and advice for travellers
In 2012, 25 032 708 tourist arrivals were registered in Malaysia. Most of them were from Asian countries, especially from Singapore, Thailand, Indonesia, Brunei, and China. In the same year, Tourism Malaysia reported an increase to 1 002 067 European travellers (from the UK, France, Germany, Netherlands, Italy, Sweden, Switzerland, Denmark, Spain, Ireland, Norway, Belgium, Austria, and Poland), 327 065 from the USA and Canada, and 573 674 from New Zealand and Australia. 59 The risk of transmission therefore appears low for intercontinental travellers considering that only 14 cases have been reported beyond endemic areas. /l # 277 U/l " 237 U/l " 0.2%
ALT, alanine aminotransferase; AST, aspartate aminotransferase; NA, information not available. a # Value lower than locally used reference value; " value higher than locally used reference value. b The year of infection was unclear, so the year of publication has been used. Since Malaysian coastal and urban areas have been declared malaria-free zones by the WHO, travellers at potentially high risk are those undertaking trips and trekking tours in forested or rural areas in the deep hinterland. A lower risk of P. knowlesi infection is reported from Thailand, but certain forested areas are considered as malaria zones. 60 The recent report of a French man acquiring a P.
knowlesi infection probably on a tourist beach on the Island of Ko Payam, Thailand, indicates a risk in coastal areas as well, particularly if they are situated near a forest. 36 People travelling to known risk areas for P. knowlesi should use malaria vector protection measures, such as insect repellents, 61 mosquito nets, mosquito coils, aerosol sprays, and protective clothes. 60 Until more specific research contradicts this doctrine, currently available chemoprophylaxis medication is effective against P. knowlesi. 54 A single case of possible resistance to mefloquine has been reported in a Malaysian businessman, as mentioned above. 55 Patients presenting in non-endemic countries with malaria-typical symptoms, such as fever, headache, malaise, (Table 2) The high rate of misdiagnosis of P. knowlesi infection as P. falciparum or P. malariae by light microscopy in non-endemic countries (Table 3) 42 The latest research on protein structures as markers for the detection of P. knowlesi, indicates promising progress in this field. 62 Until ideal commercial diagnostic tests are developed, it is Chloroquine, sulfadoxine, pyrimethamine 2 -Died Cox-Singh et al. 7 Chloroquine, sulfadoxine, pyrimethamine, primaquine Later: quinine
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Died important to use the established diagnostic tools in the most efficient way. This is especially important for infections with morphological structures similar to P. malariae on light microscopy in those with a history of travel to Malaysia and a low platelet count, who should be suspected of having a possible P. knowlesi infection. 2, 8, 9 (Table 4) Immediate hospitalization and initiation of treatment are imperative due to the 24-h replication cycle and the potential severity of the fifth human malaria. 6, 7 Indicators for a potential severe course have been described by Willmann et al. 43 and Barber et al., 42 as mentioned above. Patients showing signs of a severe knowlesi infection should be treated according to the guidelines for severe P. falciparum infections, with parenteral medication. 42, 60, 63 Several treatment regimens are reported to be effective against P. knowlesi, including the chloroquine/primaquine combination. 54 Due to the fact that no hypnozoites have ever been described in P. knowlesi infection, primaquine is probably not required as a treatment except in cases of mixed infection with P. vivax. Further studies are needed to evaluate the optimal prevention and treatment of P. knowlesi, especially in view of increasing resistance to the concomitantly occurring P. falciparum in Southeast Asia. Recent studies have shown the efficacy of ACT, such as artemetherlumefantrine and artesunate-mefloquine, in non-severe P. knowlesi infections, as well as intravenous artesunate in severe cases. 42, 64 These treatment regimens appear promising, particularly in view of the often multi-resistant, co-endemic P. falciparum and P. vivax infections. In addition, ACTs have a significantly faster parasite clearance compared to chloroquine. 64 
Conclusions
P. knowlesi appears to be a widespread human malaria parasite in Malaysian Borneo 65, 66 . This paper illustrates that the fifth human parasite is not only a threat to residents, but also to occupational and holiday travellers. Despite the increasing prevalence in Malaysia, infection rates in travellers remain low, but the extent of misdiagnosed cases remains uncertain. A special risk group are travellers to forested and rural areas. At lower, but still underestimated risk of P. knowlesi infection, are travellers to Thailand, the Philippines, Indonesia, Myanmar, and Vietnam, and probably also Cambodia. Clinicians who provide pre-travel advice or who consult ill returning travellers should be aware of the risk. Adequate preventive measures, such as mosquito nets, insect repellents, and the wearing of protective clothing, should be recommended together with appropriate antimalarials. In travellers who present with malaria-typical symptoms and a recent history of travel to Malaysia or neighbouring areas in Southeast Asia, a probable P. knowlesi infection has to be taken into consideration. If blood smears are positive for P. malariae, a P. knowlesi infection has to be strongly suspected, especially if accompanied by low thrombocyte counts. Due to the fast reproduction cycle and a potentially severe progression, patients who are suspected of having a P. knowlesi infection should be hospitalized and treated immediately.
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